Diabetol Metab Syndr 11:62 Tanaka A, Shimabukuro M, Okada Y, Taguchi I, Yamaoka-Tojo M, Tomiyama H, Teragawa H, Sugiyama S, Yoshida H, Sato Y, Kawaguchi A, Ikehara Y, Machii N, Maruhashi T, Shima KR, Takamura T, Matsuzawa Y, Kimura K, Sakuma M, Oyama JI, Inoue T, Higashi Y, Ueda S, Node K (2017) EMBLEM Trial Investigators
Learners also explore a mock competitive analysis as well as a discussion of sales financials and a sample revenue model
But in the beginning of last year, we, we said, no, it has to be for a diabetes prescription. -Senior Human Resources Leader, large services organization The use of GLP-1 agonists was higher than expected for many large employers including for over half (59%) of employers over 5,000 workers Since then, many larger employers covering GLP-1 agonists for weight loss reported higher than expected use of the medications and significant impacts on their prescription spending
Gower BA, Chandler-Laney PC, Ovalle F, et al
The REWIND trial's cognitive substudy with dulaglutide and smaller trials of liraglutide in Alzheimer's disease have shown modest or inconsistent effects
